TFX official logo TFX
TFX 1-star rating from Upturn Advisory
Teleflex Incorporated (TFX) company logo

Teleflex Incorporated (TFX)

Teleflex Incorporated (TFX) 1-star rating from Upturn Advisory
$116.17
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/02/2025: TFX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

3 star rating from financial analysts

14 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $124.14

1 Year Target Price $124.14

Analysts Price Target For last 52 week
$124.14 Target price
52w Low $102.26
Current$116.17
52w High $186.79

Analysis of Past Performance

Type Stock
Historic Profit -23.67%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/02/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.13B USD
Price to earnings Ratio -
1Y Target Price 124.14
Price to earnings Ratio -
1Y Target Price 124.14
Volume (30-day avg) 14
Beta 0.95
52 Weeks Range 102.26 - 186.79
Updated Date 12/3/2025
52 Weeks Range 102.26 - 186.79
Updated Date 12/3/2025
Dividends yield (FY) 1.19%
Basic EPS (TTM) -7.28

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-11-06
When -
Estimate 3.38
Actual 3.67

Profitability

Profit Margin -10.28%
Operating Margin (TTM) 12.4%

Management Effectiveness

Return on Assets (TTM) 4.94%
Return on Equity (TTM) -7.9%

Valuation

Trailing PE -
Forward PE 7.58
Enterprise Value 7471439219
Price to Sales(TTM) 1.61
Enterprise Value 7471439219
Price to Sales(TTM) 1.61
Enterprise Value to Revenue 2.34
Enterprise Value to EBITDA 142.75
Shares Outstanding 44194408
Shares Floating 41709356
Shares Outstanding 44194408
Shares Floating 41709356
Percent Insiders 0.33
Percent Institutions 108.28

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Teleflex Incorporated

Teleflex Incorporated(TFX) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Teleflex Incorporated was founded in 1943 as a manufacturer of mechanical remote control systems. Over the years, it has evolved through acquisitions and organic growth to become a global provider of medical technology products and services.

Company business area logo Core Business Areas

  • Vascular Solutions: This segment develops, manufactures, and markets a range of devices used in interventional cardiology and radiology procedures, including guide wires, catheters, and access devices.
  • Interventional Urology: This segment provides solutions for urological procedures, including devices for managing enlarged prostates and urinary obstructions.
  • Surgical Solutions: Offers specialized surgical instruments, sutures, and ligation devices for various surgical specialties.
  • Anesthesia: Provides a range of anesthesia and respiratory products, including laryngeal masks and airway management devices.
  • OEM: Teleflex partners with OEM clients to provide component assembly and finished medical devices

leadership logo Leadership and Structure

Teleflex is led by Liam J. Kelly (Chairman, President and CEO). The company has a hierarchical organizational structure with various business units reporting to executive leadership.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Arrow EZ-IO Intraosseous Vascular Access System: A device used to establish immediate vascular access in emergency situations. Competitors include Vidacare (Teleflex acquired them) and PerSys Medical. Market share difficult to pinpoint exactly, but it's a significant player in the IO access market.
  • LMA Airway Management Devices: A range of laryngeal mask airways used for anesthesia and airway management. Competitors include Ambu and Smiths Medical. Teleflex holds a significant market share in the global laryngeal mask airway market.
  • UroLift System: A minimally invasive technology for treating enlarged prostates (BPH). Competitors include Boston Scientific (ProAccess) and Olympus (Plasma Resection). UroLift is a key product driving growth in Interventional Urology.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by innovation, regulation, and consolidation. Demand is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements.

Positioning

Teleflex is positioned as a diversified medical technology company focused on niche markets and minimally invasive procedures. Its competitive advantages include a strong portfolio of branded products, established distribution channels, and a focus on innovation.

Total Addressable Market (TAM)

The total addressable market across Teleflex's segments is estimated to be several billion dollars annually. Teleflex is well-positioned to capture a significant portion of this market through product innovation and market expansion.

Upturn SWOT Analysis

Strengths

  • Diversified product portfolio
  • Strong brands in key market segments
  • Focus on minimally invasive procedures
  • Established distribution channels
  • History of successful acquisitions

Weaknesses

  • Dependence on certain key products
  • Exposure to regulatory risks
  • Integration challenges with acquisitions
  • Competition from larger medical device companies
  • Currency exchange rate fluctuation

Opportunities

  • Expansion into emerging markets
  • Development of new products and technologies
  • Strategic acquisitions to expand product portfolio
  • Increased adoption of minimally invasive procedures
  • Partnerships and collaborations with other healthcare providers

Threats

  • Increased competition from established and emerging players
  • Pricing pressures from healthcare providers
  • Changes in healthcare regulations and reimbursement policies
  • Product liability lawsuits
  • Economic downturns affecting healthcare spending

Competitors and Market Share

Key competitor logo Key Competitors

  • BSX
  • MDT
  • ABT
  • BMRN

Competitive Landscape

Teleflex competes with larger medical device companies in many of its segments. It differentiates itself through its focus on niche markets, branded products, and minimally invasive procedures.

Major Acquisitions

Standard Bariatrics, Inc.

  • Year: 2022
  • Acquisition Price (USD millions): 300
  • Strategic Rationale: Expanded the company's bariatric surgery solutions and strengthened the surgical solutions segment.

Growth Trajectory and Initiatives

Historical Growth: Teleflex has historically grown through organic growth and strategic acquisitions.

Future Projections: Future growth projections depend on market conditions and analyst predictions. Refer to equity research reports.

Recent Initiatives: Recent initiatives include new product launches, strategic acquisitions, and cost optimization programs.

Summary

Teleflex is a well-positioned medical technology company with a diversified portfolio and a focus on minimally invasive procedures. Its growth strategy relies on innovation, acquisitions, and expansion into emerging markets. Regulatory risks and competition remain key challenges. Financials need to be observed directly on the company websites for accurate assessment. While they appear sound, individual performance must be validated through the use of their direct website. The company focuses on driving shareholder value and has a strong team running the company.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Teleflex Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Equity Research Reports
  • Industry Analysis Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may not be precise.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Teleflex Incorporated

Exchange NYSE
Headquaters Wayne, PA, United States
IPO Launch date 1988-02-18
Chairman, President & CEO Mr. Liam J. Kelly
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 14100
Full time employees 14100

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.